PECULIARITIES OF ANABOLIC-CATABOLIC BALANCE IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT METABOLIC PHENOTYPES
DOI:
https://doi.org/10.21856/j-PEP.2023.1.03Keywords:
type 2 diabetes, uric acid metabolism, body composition, anabolic-catabolic balanceAbstract
Objective: to study the characteristics of uric acid (UA) production and excretion in relation to body composition and lipid spectrum in type 2 diabetic men and women with obesity and non-obese phenotypes.
Results. The examined 150 patients with type 2 diabetes (88 men, 62 women), separately men and women, were divided into 2 groups according to the degree of obesity: 1) non-obese (BMI<30 kg/m2; n = 61); 2) obesity of varying degrees (BMI≥30 kg/m2; n = 89). Patients with the obese phenotype have higher uricemia, lower fraction urate excretion, higher activity of purine reutilization enzyme, hypoxanthine guanine phosphoribosyl transferase (HGPRT), higher levels of insulin secretion, and decreased urates excretion. The division of patients into the groups according to visceral fat (VF) level, showed that the abdominal obesity phenotype (VF>12 units) increased the UA level in women with high VF and in both groups of men, probably under the influence of higher insulin levels and reduced fractional excretion of urates.
Conclusions. Hyperproduction of uric acid in type 2 diabetic patients with different phenotypes may have different basis: while in obese subjects, the anabolic processes dominate, accompanied by accumulation of total and visceral fat, increased lipogenesis and purine synthesis, the non-obese phenotype is characterized by dominating of catabolic pathways that cause lipolysis, purine degradation and production of the end product, uric acid.
References
Buse JB, Wexler DJ, Tsapas A, et al. Diabetologia 2020;63: 221-228. https://doi.org/10.2337/dci19-0066
Alizadeh S. Endocrinol Metab 2019;63(4): 427-437. https://doi.org/10.20945/2359-3997000000149.
Muriel P, López-Sánchez Р, Ramos-Tovar E. Int J Mol Sci 2021;22(6969): 1-22. https://doi.org/10.3390/ijms22136969.
Tsushima Y, Nishizawa H, Tochino Y, et al. J Biol Chem 2013;288(38): 27138-27149. https://doi.org/10.1074/jbc.M113.485094.
Chiang KM, Tsay YC, Ng TC, et al. J Clin Med 2019;8(8): 1202. https://doi.org/10.3390/jcm8081202.
Pujia R, Tarsitano M, Arturi F, et al. Front Nutr 2022;9: 804719. https://doi.org/10.3389/fnut.2022.804719
Xu Z, Liu Y, Yan C, et al. BMJ Open 2021;11(10): e048221. https://doi.org/10.1136/bmjopen-2020-048221.
Abolhasani M, Maghbouli N, SazgaraF, et al. Diab Metab.Syndr Obes 2020;13: 2327-2336. https://doi.org/10.2147/DMSO.S254741
Czeczelewski M, Czeczelewski J, Galczak-Kondraciuk A. Obes Medic 2020;17: 100171. https://doi.org/10.1016/j.ypmed.2014.07.001.
Wildman R, Muntner P, Reynolds K, et al. Arch Intern Med 2008;168: 1617-1624. https://doi.org/10.1001/archinte.168.15.1617.
Alizadeh S. Arch Endocrinol Metab 2019;63(4): 427-437. https://doi.org/10.20945/2359-3997000000149.
Eckel N, Mühlenbruch, Meidtner K, et al. Metabolism 2015;64(8): 862-871. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.
Ding C, Chan Z, Magkos F. Curr Opin Clin Nutr Metab Care 2016;19(6): 408-417. https://doi.org/10.1097/MCO.0000000000000317.
Sculley DG, Dawson PA, Emmerson BT, Gordon RB. Human Genetics 1992;90(3): 195-207. https://doi.org/10.1007/BF00220062.
Amato M, Giordano C, Galia M, Criscimanna A. Diab Care 2010;33(4): 920-922. https://doi.org/https://doi.org/10.2337/dc09-1825.
Lee S, Lacy M, Jankowich M, et al. J Clin Transl Endocrinol 2019;19: 100210. https://doi.org/10.1016/j.jcte.2019.100210.
Chiang K, Tsay Y, Ng T, et al. J Clin Med 2019;8(8): 1202. https://doi.org/10.3390/jcm8081202
Wang Y, Charchar FJ. Sci Rep 2021;11: 17323. https://doi.org/10.1038/s41598-021-96959-4
Han Y, Zhang Y, Cao Y, et al. Transl Androl Urol 2021;10(1): 272-282. https://doi.org/10.21037/tau-20-1114.
Yu J, Sun H, Zhu J, et al. Diab Metab Syndr Obes 2021;14: 1367-1374. https://doi.org/10.2147/DMSO.S301363
Eun Y, Kim IY, Han K, et al. Arthritis Res Ther 2021;23: 304. https://doi.org/10.1186/s13075-021-02701-w
Gong M, Wen S, Nguyen T, et al. Diab Metab Syndr Obes 2020 13: 943-962. https://doi.org/10.2147/DMSO.S232377.
Ragab G, Elshahaly M, Bardin T. J Adv Res 2017;8(5): 495-511. https://doi.org/10.1016/j.jare.2017.04.008
Pribyla OV, Zinich OV, Korpachev VV, et al. Ukr Med J 2020;137(V/VI): 31-37. https://doi.org/10.32471/umj.1680-3051.137.182448.
Yatsyshyn RI, Migovich VV. Ukr Rheumatologist J 2010;4(42): 50-54, available at: https://www.rheumatology.kiev.ua
Sinyachenko OV, Bryzhataya YuO, Yakubenko ED. Ukr Rheumatologist J 2014;58(4): 80-84, available at: https://www.rheumatology.kiev.ua
Dudko OV. Cur Iss Pharm Med Sci Pract 2022;15(1). https://doi.org/10.14739/2409-2932.2022.1.246775
Tovchyga OV. Antidiabetic and organotropic action of comfrey (Aegopodium podagraria l.) аnd their combinations with antihyperglycemic, diuretic and hypouricemic drugs, Kharkiv, 2019: 44 p.
Doholich OI, Voloshin OI. Bukovyn Med Bull 2014;18(3): 64-68, available at: http://nbuv.gov.ua/UJRN/bumv_2014_18_3_19
Chung S, Kim GH. Electrolyte Blood Press 2021;19(1): 1-9. https://doi.org/10.5049/EBP.2021.19.1.1
Takiue Y, Hosoyamada M, Kimura M, Saito H. Nucleos Nucleot Nucl Acids 2011;30(2): 113-119. https://doi.org/10.1080/15257770.2010.551645
Gus E, Shahrokhi S, Jeschke M. Burns 2020;46(1): 19-23. https://doi.org/10.1016/j.burns.2018.03.009.
ISSN 
ISSN 
